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Abstract
Background: Recent research has established correlations between stress, anxiety, insomnia and
excess body weight and these correlations have significant implications for health. This study
measured the effects of a proprietary blend of extracts of Magnolia officinalis and Phellodendron
amurense (Relora®) on anxiety, stress and sleep in healthy premenopausal women.
Methods: This randomized, parallel, placebo controlled clinical study was conducted with healthy,
overweight (BMI 25 to 34.9), premenopausal female adults, between the ages of 20 and 50 years,
who typically eat more in response to stressful situations and scores above the national mean for
women on self-reporting anxiety. The intervention was Relora (250 mg capsules) or identical
placebo 3 times daily for 6 weeks. Anxiety as measured by the Spielberger STATE-TRAIT
questionnaires, salivary amylase and cortisol levels, Likert Scales/Visual Analog Scores for sleep
quality and latency, appetite, and clinical markers of safety. The study was conducted by Miami
Research Associates, a clinical research organization in Miami, FL.
Results: The intent-to-treat population consisted of 40 subjects with 26 participants completing
the study. There were no significant adverse events. Relora was effective, in comparison to placebo,
in reducing temporary, transitory anxiety as measured by the Spielberger STATE anxiety
questionnaire. It was not effective in reducing long-standing feelings of anxiety or depression as
measured using the Spielberger TRAIT questionnaire. Other assessments conducted in this study
including salivary cortisol and amylase levels, appetite, body morphology and sleep quality/latency
were not significantly changed by Relora in comparison to placebo.
Conclusion: This pilot study indicates that Relora may offer some relief for premenopausal
women experiencing mild transitory anxiety. There were no safety concerns or significant adverse
events observed in this study.
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Background
Recent research has established correlations between
stress, anxiety, insomnia and excess body weight and
these correlations have significant implications for health.
Substantial and prolonged stress and anxiety can cause
adverse health effects to the immune function, hormone
levels, enzymes and gastrointestinal function. Recently
links have been established between chronic stress and
obesity [1,2]. Increased levels of the stress hormone, cor-
tisol, have been correlated to increased eating of high
caloric foods and sweets. Additionally, among people
who identified themselves as "stress eaters," weight gain
tended to increase over time [3]. It is also known that
stress worsens insomnia, and insomnia has been linked to
overweight and obesity [4,5]. Among 6,115 people, ages
32–59, comparisons were made between the weights of
those who slept for a normal period of time (7–9 hours)
and those who slept for shorter or longer periods of time.
Those who slept for shorter periods of time than normal
were more likely to be obese and those who slept for
longer periods of time were less likely to be obese. Those
who slept 2–4 hours per night, 5 hours per night or 6
hours per night were respectively 73%, 50% and 23%
more likely to be obese. Those who slept for 10 or more
hours were 11% less likely to be obese [5].
Interventions for stress and anxiety range from nutritional
support to the use of medications such as benzodi-
azepines and selective serotonin reuptake inhibitors.
Recently a United States Patent (No 6,582,735) was
granted for the use of an extract of Magnolia officinalis bark
for stress related conditions involving elevated cortisol,
such as control of body weight, sleep disturbances and
restlessness.
Extracts of Magnolia officinalis bark and its active constitu-
ent, honokiol, have been studied in various mouse mod-
els that have compared the activity to diazepam (a
benzodiazepine anxiolytic used to treat anxiety disorders
since the 1960's) [6-8]. The studies found that honokiol
had an anxiolytic effect without the common side effects
of diazepam (motor dysfunction, sedation or amnesia).
The Magnolia officinalis bark extract and an extract of Phel-
lodendron amurense bark were tested in an animal model
for stress, the Chick Social Separation Stress Procedure,
with positive results [9]. Both extracts reduced distress
vocalization and stress-induced analgesia without causing
sedation. Berberine, a constituent of the Phellodendron
extract, has demonstrated a significant anxiolytic effect in
the black and white and the elevated plus maze tests in
mice [10]. Berberine has also demonstrated an antidepres-
sant effect in the forced swim test in mice [11].
The subject of this study, Relora® (Next Pharmaceuticals,
Inc, Salinas, CA), is a proprietary dietary supplement for-
mulation consisting of a blend of extracts of Magnolia
officinalis bark and Phellodendron amurense bark standard-
ized to honokiol and berberine, respectively.
In previously conducted trials by the study sponsor
(unpublished in-house data), Relora has demonstrated
some efficacy for reducing perceived anxiety and enhanc-
ing feelings of well-being. One study also measured the
effects of Relora on salivary cortisol and found that it had
some effect on morning cortisol while also raising dehy-
droandrostenedione levels (DHEA).
The purpose of this study was to conduct a placebo-con-
trolled clinical trial to determine the effects of Relora on
anxiety using psychometric questionnaires, cortisol levels
and sleep (questionnaires). A part of this study that inves-
tigated the effects of Relora on stress-related changes in
body weight has previously been published [12].
Materials and methods
Test Material
Relora® (NP 33–39) is a proprietary blend of a patented
extract of the bark of Magnolia officinalis Rehder & Wilson
[Magnoliaceae] (US Patent Nos. 6,582,735 and
6,814,987) and an extract of the bark of Phellodendron
amurense Rupr. [Rutaceae]. The product is standardized to
not less than 1.5% honokiol and 0.1% berberine. Subjects
ingested 250 mg in dark red opaque capsules three times
daily or a placebo that was identical in size, shape and
color.
Study Design
In a prospective, two-group, parallel, randomized, dou-
ble-blind, placebo-controlled trial design, healthy adult
females with anxiety who reported that they typically eat
more in response to stressful situations were enrolled and
followed for six weeks. Participants were split into two
groups of 20 using block code randomization (coded
labels provided by the manufacturer) and then adminis-
tered either Relora or a matched placebo for six weeks. The
study was approved by the Integreview Ethical Review
Board, Austin, TX.
Recruitment advertisements were placed in English and
Spanish in local newspapers in the Miami, FL, area. The
advertisements read, "Is stress making you eat? You may
qualify to participate in a research study of a nutritional
supplement for people who eat more during stressful sit-
uations. To qualify you must not be taking medications
for depression or anxiety, be overweight but in good gen-
eral health, be 20 to 50 years of age, and be a premeno-
pausal female." The subjects for the study were pre-
screened by phone and potential candidates were called in
for a screening and baseline evaluation (Visit 1) after pro-
viding written informed consent. Acceptable subjects wereNutrition Journal 2008, 7:11 http://www.nutritionj.com/content/7/1/11
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enrolled (Visit 2), and then randomized with equal prob-
ability to receive either Relora or placebo. Efficacy and
safety evaluations were performed during visits at treat-
ment weeks 3 and 6 (Visits 3 and 4).
To be included in the study, subjects had to be healthy
overweight females (BMI 25 – 39.9 kg/m2), be premeno-
pausal (aged 25 to 50) and to self report increased eating
in response to stress. Subjects were excluded if they had
personal history of heart disease, uncontrolled high blood
pressure, renal or hepatic impairment/disease, Type I or II
diabetes, psychiatric disorders, cancer (except basal cell
carcinoma of > 5 years ago), use of any monoamine oxi-
dase inhibitor medication, sleep disorders, glaucoma, gas-
tric ulcer or reflux disease or a seizure disorder, unstable
thyroid disease, pregnancy, lactation, or any medical con-
dition deemed exclusionary by the medical staff. Scores
positive for Binge Eating Disorder utilizing the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV) cri-
teria for diagnosis (score > 7), or scores positive for clini-
cal depression via the Center for Epidemiologic Studies
Depression Scale (CES-D) questionnaire (scores >16) or
score below the norm for women 30 – 39 years of age on
the State-Trait Anxiety Inventory (STAI) (< 34; per investi-
gator discretion) or if the subject scored positively for
severe anxiety they were also excluded from this study.
Psychiatric disorders were determined by medical history,
rechecked by the Principal Investigator (a medical doc-
tor), and by means of questionnaires given by trained pro-
fessionals. Subjects were also excluded if they were on
monoamine oxidase inhibitors (MAO-I), anxiolytics, psy-
chotropics including SSRI's, daily use of OTC medications
or were currently taking stimulant medications (prescrip-
tion, self-prescribed or OTC). In addition, recent use of
weight control agents, unstable body weight, use of any
form of a steroid medication, use of any type of dietary
supplement were also excluded. Women who were preg-
nant, lactating, planning to become pregnant during the
study or not using an acceptable form of contraceptive
device or if a subject was ever diagnosed with Post-trau-
matic stress disorder (PTSD), they were excluded from this
study. Study subjects were not allowed to take supple-
ments that are, or were purported, to affect mood states.
They were also not allowed to start any new supplements.
If a subject was already taking a multivitamin/mineral
supplement, they were allowed to continue doing so. To
ensure compliance, a dichotomous questionnaire was
used by the coordinator at each visit.
Analyses
Blood was drawn for analysis of biochemical markers for
safety parameters at the beginning and end of the study. A
3-day (2 working days and 1 non-working day) food diary
was recorded by the subjects at baseline and post-treat-
ment. At the beginning, mid-point and end of the study,
participants were weighed and tested using psychometric
questionnaires. The psychometric questionnaires used in
this study included: Spielberger STATE-TRAIT (20-item
questionnaires by which subjects describe transient or
general anxiety, on a 4-level scale); Visual Analog Scale –
Sleep Quality (VAS-SQ; 10 cm scale, self-reported 5 point
Likert scale, 0 = no sleep, 4 = very restful sleep); Sleep
Latency Questionnaire – asked each time the VAS-SQ was
conducted; subjective notion of how long, on average it
takes the person to fall asleep, in minutes); and subjects
were also given 3-day saliva collection kits (to be analyzed
for salivary amylase and salivary cortisol) at the screening
and mid-study visits (with samples taken at three different
times (upon waking, 30 minutes later, and in the evening)
for three consecutive days during each collection cycle), to
be collected at the randomization and end-of-study visits,
respectively.
Participants were also asked to follow their typical diets
and exercise routines. Physical exercise quantity was
quantified with the Framingham Physical Activity Index.
Statistical Plan
The primary efficacy analyses were conducted on an
Intent-to-Treat basis, with missing observations imputed
by the "last observation carried forward" (LOCF) method.
Safety analyses were conducted on all subjects who
received study product. Unpaired t-tests were used to com-
pare changes over time between the two groups, except for
variables that were substantially non-normally distrib-
uted, in which case the Mann-Whitney U-Test was
employed. Statistical analysis was conduced using Excel
2002, SPSS version 13.0 and "R" version 2.1.1.
The number of participants for this study was pre-deter-
mined as a convenience sample. It was noted that a sam-
ple size of 20 subjects in each of two groups could provide
80% probability to produce a significant result (P < 0.05)
in an unpaired comparison, when the mean between-
group difference in any endpoint is 0.9 as large as the
within-group standard deviation for that endpoint.
Results
Study Population
Forty two female subjects, aged 25–50 (mean 38.6 ± 6.1,
BMI of 31.2 ± 4.1 kg/m2) were enrolled and randomized
into two test groups. Two of the subjects were subse-
quently discovered to be outside of the inclusion/exclu-
sion criteria and were subsequently excluded from all but
safety analysis. There were no statistical differences
between groups at baseline in scores for age, ethnicity,
anthropometry (height, weight, BMI, waist and hip cir-
cumference and waist-to-hip ratio). There were no clinical
differences in vital signs (heart rate, blood pressure) or lab
tests (glucose, creatinine, blood urea nitrogen, alkalineNutrition Journal 2008, 7:11 http://www.nutritionj.com/content/7/1/11
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phosphatase, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), white blood cell count, hemo-
globin, hematocrit, thyroid stimulating hormone). There
was one slight statistical difference in serum ALT (17.4 ±
8.4 vs 23.6 ± 10.1 IU, respectively for treatment and pla-
cebo; p = 0.032) but this was not considered of clinical
importance. There were no statistical differences between
the two groups in the psychometric measures listed in the
Methods section.
The intent-to-treat population consisted of 40 subjects.
Sixteen participants in the treatment group and ten partic-
ipants in the control group completed the study. Nine
subjects, one in the treatment group and eight in the con-
trol group, were lost to follow-up. Five subjects, three in
the treatment group and two in the placebo group, termi-
nated early for various reasons. Three subjects withdrew
due to adverse events: two in the treatment group, one in
the placebo group (see Table 1). The researchers could not
determine the reason for discrepancy in the difference in
dropouts between placebo and the active groups. Compli-
ance in the intent-to-treat population was 90.6 ± 11.5% in
the Relora group and 86.1 ± 23.4% in the placebo group,
with no statistical difference between them.
Safety
The safety population consisted of all subjects who con-
sumed any product and who had some post-dose follow-
up safety observations. It included 39 subjects. No serious
adverse events were noted in this study. Two subjects in
the treatment group and one in the placebo group
dropped out of the study early due to adverse events. One
subject in the Relora group complained of heartburn,
hands shaking, perilabial numbness, sexual dysfunction,
and thyroid dysfunction. The second subject in the Relora
group complained of fatigue and headache. The subject in
the placebo group complained of irritability, abdominal
bloating and tiredness. No significant changes were noted
in vital signs during the course of the study. No laboratory
values showed significant differences between treatment
and placebo in mean changes from baseline to the end of
the study.
Efficacy
The primary objective of the study was to determine the
effects of Relora, compared to placebo, on mild anxiety.
The Spielberger STATE and TRAIT anxiety questionnaires
were given to subjects at screening and after 6 weeks of
treatment. There were significant decreases (less anxiety)
in the total STATE score over time for both treatment and
placebo groups with the average decrease being almost
twice as much for the Relora group (-14.3 ± 12.1 and -7.6
± 9.8, respectively). The reduction in anxiety was signifi-
cantly greater for the treatment group compared to the
placebo group (p = 0.045) (Table 2).
According to the Spielberger TRAIT questionnaire, Relora
significantly reduced general and longer lasting anxiety
over the 6 weeks (-12.2 ± 10.4; p < 0.001). The placebo
group also had a significant decrease in score (-7.6 ± 10.2;
p = 0.004). When the average change over time for the two
groups was compared, there was no significant difference
between the two (Table 3).
At the end of the study, the subjects were given a question-
naire to assess their perceived stress or anxiety. The Relora
group reported that they experienced a significant reduc-
tion in perceived anxiety/stress (p = 0.043) compared to
placebo (see Table 4). The subjects were asked: On a scale
of 1 to 5 with 1 being the lowest possible difference and 5
being the best change or difference: Do you feel that tak-
ing the supplement helped to reduce your perceived stress
or anxiety? The Relora group average score was a 4, while
placebo average score was a 2.
Levels of salivary cortisol and amylase were measured.
Samples were taken at three different times of the day
(upon waking, 30 minutes later and in the evening) for
three consecutive days during two collection cycles (base-
line and at six weeks). There was a trend towards decreases
in cortisol levels at all time points in both groups, but
none of these changes reached statistical difference and
there was no significant difference between groups. Sali-
vary amylase levels increased significantly in the evening
in the treatment group (change from 29.8 ± 23.5 to 37.8
± 31.5, a total change of 8.0 ± 12.4, p = 0.025), but this
change was not significant when compared to the placebo
group.
Table 1: Disposition of Enrolled Subjects
Disposition Relora Placebo Total p value
Completed per protocol 16 (80%) 10 (50%) 26 (65%)
Early Termination 3 (15%) 2 (10%) 5 (12%) 0.030
Lost to Follow-up 1 (5%) 8 (40%) 9 (22%)
Total 20 (100%) 20 (100%) 40 (100%)
Disposition of enrolled subjects is listed in the table with the percentage of the total listed in parenthesis. The p-value in the column on the right 
compares those who terminated early, based upon the Fisher Exact test.Nutrition Journal 2008, 7:11 http://www.nutritionj.com/content/7/1/11
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Appetite levels, dietary restraint, as well as intakes of calo-
ries, protein, carbohydrate and fat were measured at the
beginning and the end of the study but there were no con-
sistent changes when the Relora and placebo groups were
compared. There were also no statistical changes in
weight, waist circumference, hip circumference or waist/
hip ratio when the two groups were compared.
Quality of sleep did not change statistically for either
group and there was no difference between groups. Sleep
latency was determined by a questionnaire: During the
past month, how long (in minutes) has it usually taken
you to fall asleep each night? Subjects in the treatment
group reported a decrease in sleep latency (change from
33.7.8 ± 29.5 to 22.6 ± 22.1, a total decrease of 11.1 ± 17.2
minutes, p = 0.012), but this change was not significant
when compared to the placebo group.
Discussion
Relora® significantly reduced anxiety compared to placebo
as determined by the Speilberger STATE anxiety question-
naire. This questionnaire measures temporary, transitory
anxiety that includes feelings of apprehension, tension,
nervousness and worry that increase in response to physi-
cal danger and psychological stress. The questionnaire
measures how the respondents feel "right now, at this
moment" [13]. This measurement has been used in coun-
seling and to measure the effects of relaxation training.
General, consistent, long-standing feelings of anxiety or
depression were measured using the Spielberger TRAIT
questionnaire. In this questionnaire, psychoneurotic and
depressed patients tend to have high scores [13]. Accord-
ing to this measurement, Relora and placebo each signifi-
cantly reduced general anxiety over the 6 weeks. There was
no statistical difference compared to the placebo group.
The State-Trait Anxiety Inventory (STAI) was initially con-
ceptualized as a research instrument for the study of anxi-
ety in adults. It is a self-report assessment device which
includes separate measures of state and trait anxiety.
Scores on the STAI have a direct interpretation: high scores
on their respective scales mean more trait or state anxiety
and low scores mean less. Both percentile ranks and
standard scores are available for male and female working
adults in three age groups (19–39, 40–49, 50–69). The
stability of the STAI scales have been assessed on male and
female samples of high school and college students for
test-retest intervals ranging from one hour to 104 days.
The magnitude of the reliability coefficients decreased as
a function of interval length. For the Trait-anxiety scale the
coefficients ranged from 0.65 to 0.86, whereas the range
for the State-anxiety scale was 0.16 to 0.62. This low level
of stability for the State-anxiety scale is expected since
responses to the items on this scale are thought to reflect
the influence of whatever transient situational factors exist
at the time of testing. Correlations between this scale and
other measures of trait-anxiety: the Taylor Manifest Anxi-
Table 2: Spielberger State Total Score
Time Point Relora (N = 20) Placebo (N = 20) Comparison p values
Screening 32.5 ± 7.6
33 (19 – 47)
29.4 ± 6.7
29.5 (18 – 43)
0.166
Week 6 18.2 ± 8.6
17.5 (1 – 38)
21.7 ± 9.8
20.5 (1 – 43)
0.245
Change from Baseline to Week 6 -14.3 ± 12.1
-16 (-34 – 9)
p < 0.001
-7.6 ± 9.8
-2.5 (-34 – 2)
p = 0.005
0.045
Values are listed in the following format: Mean ± Standard Deviation; Median (Minimum-Maximum). The values in the bottom row are average 
changes from baseline and the p-values are based upon single-group Student t-tests or non-parametric equivalent. P-values listed in the column to 
the right compare the two groups and are based upon an unpaired Student t-test or non-parametric equivalent.
Table 3: Spielberger Trait Total Score
Time Point Relora (N = 20) Placebo (N = 20) Comparison p values
Screening 38.5 ± 10.6
41.5 (20 – 59)
36.5 ± 9.9
36.5 (12 – 53)
0.531
Week 6 26.4 ± 5.6
25.5 (19 – 42)
28.9 ± 10.1
26 (12 – 53)
0.341
Change from Baseline to Week 6 -12.2 ± 10.4
-12 (-31 – 7)
p < 0.001
-7.6 ± 10.2
-2.5 (-35 – 0)
p = 0.004
0.156
Values are listed in the following format: Mean ± Standard Deviation; Median (Minimum-Maximum). The values in the bottom row are average 
changes from baseline and the p-values are based upon single-group Student t-tests or non-parametric equivalent. P-values listed in the column to 
the right compare the two groups and are based upon an unpaired Student t-test or non-parametric equivalent.Publish with BioMed Central    and   every 
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ety Scale, the IPAT Anxiety Scale, and the Multiple Affect
Adjective Check List are 0.80, 0.75, and 0.52, respectively
[11].
Thus, in this short 6-week study Relora was effective, in
comparison to placebo, in reducing temporary, transitory
anxiety as measured by the Spielberger STATE anxiety
questionnaire. It was not effective in reducing long-stand-
ing feelings of anxiety or depression as measured using the
Spielberger TRAIT questionnaire. Relora was also effective
in reducing self-perceived stress or anxiety. These results
are consistent with those observed in the uncontrolled
open label studies previously conducted.
Other assessments conducted in this study including sali-
vary cortisol and amylase levels, appetite, body morphol-
ogy and sleep quality/latency were not significantly
changed by Relora in comparison to placebo. There are
trends that suggest that a larger study conducted over a
longer period of time might show efficacy in these varia-
bles, as well.
Conclusion
This pilot study indicates that Relora® may offer some
relief for premenopausal women experiencing mild tran-
sitory anxiety. There were no safety concerns or significant
adverse events observed in this study. Further studies with
a larger number of participants are recommended to
explore the anxiolytic effect of Relora and to determine
whether that effect may be accompanied by a reduction in
stress, in appetite, and an improvement in sleep.
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